Segmental ureterectomy is increasingly adopted for high-risk upper tract urothelial carcinoma.
A recent study characterized disease recurrence patterns and predictive risk factors for recurrence in patients who underwent radical nephroureterectomy for low-grade upper tract urothelial carcinoma.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.
A study showed that 2- and 5-year overall survival rates did not differ significantly between patients who underwent metastasectomy and those who did not.
Nivolumab treatment for patients who have undergone radical surgery for high-risk muscle-invasive urothelial carcinoma improves their disease-free survival compared with placebo, a study shows.
Compared with no ureteroscopy or percutaneous biopsy, ureteroscopic biopsy in patients with upper tract urothelial carcinoma was significantly associated with a 40% increased risk for intravesical recurrence of disease.
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.